title: ESR1 single nucleotide polymorphisms predict breast cancer susceptibility in the central European Caucasian population.
abstract: Estrogen and progesterone hormones are key regulators of a wide variety of biological processes. In addition to their influence on reproduction, cell differentiation and apoptosis, they affect inflammatory response, cell metabolism and most importantly, they regulate physiological breast tissue proliferation and differentiation as well as the development and progression of breast cancer. In order to assess whether genetic variants in the steroid hormone receptor gene ESR1 (estrogen receptor alpha) had an effect on sporadic breast cancer susceptibility, we assessed 7 ESR1 single nucleotide polymorphisms (SNPs) for associations with breast cancer susceptibility and clinical parameters in 221 breast cancer patients and 221 controls, respectively. We identified ESR1 intron SNP +2464 C/T (rs3020314) and ESR1 intron SNP -4576 A/C (rs1514348) to correlate with breast cancer susceptibility and progesterone receptor expression status. Patients genotyped CT for ESR1 intron SNP +2464 (rs3020314) (p ≤ 0.045) or genotyped AC for ESR1 intron SNP -4576 (rs1514348) (p ≤ 0.000026) were identified to carry a significant risk as to the development of breast cancer in the Central European Caucasian population (both together: p ≤ 0.000488). Our study could confirm previous associations and revealed new associations of SNP rs1514348 with susceptibility to breast cancer and clinical outcome, which might be used as new additional SNP markers.
authors: Department of Internal Medicine, Division of Immunotherapy and Gene Therapy, José Carreras Research Center, Saarland University Medical Center D-66421 Homburg/Saar, Germany.
authors: Mark F
authors: MF
authors: Lipphardt
authors: Mustafa
authors: M
authors: Deryal
authors: Mei Fang
authors: MF
authors: Ong
authors: Werner
authors: W
authors: Schmidt
authors: Ulrich
authors: U
authors: Mahlknecht
keywords: ESR1; Estrogen receptor; SNP; breast cancer
references: J Steroid Biochem Mol Biol. 1999 Nov;71(1-2):21-7
references: 10619354
references: Breast Cancer Res Treat. 2011 Oct;129(3):901-7
references: 21528353
references: PLoS Genet. 2007 Mar 16;3(3):e42
references: 17367212
references: Breast Cancer Res. 2004;6(4):R437-49
references: 15217512
references: J Natl Cancer Inst. 2011 Mar 2;103(5):425-35
references: 21263130
references: Nat Genet. 2009 Mar;41(3):324-8
references: 19219042
references: Cancer Res. 2004 Dec 15;64(24):8891-900
references: 15604249
references: Int Psychogeriatr. 2009 Oct;21(5):977-86
references: 19586561
references: Int J Cancer. 2009 Dec 1;125(11):2687-96
references: 19551860
references: BMC Cancer. 2006 May 03;6:114
references: 16672066
references: Breast Cancer Res Treat. 2007 Dec;106(2):273-80
references: 17268813
references: Nat Genet. 2007 Mar;39(3):352-8
references: 17293864
references: Cancer Res. 2011 Feb 15;71(4):1344-55
references: 21303983
references: Breast Cancer Res. 2011 Jan 26;13(1):R10
references: 21269472
references: Biol Reprod. 2006 Jul;75(1):9-16
references: 16571873
references: Hum Mol Genet. 2009 Mar 15;18(6):1131-9
references: 19126777
references: Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):255-9
references: 19124506
references: Int J Cancer. 2011 Oct 1;129(7):1689-98
references: 21105050
references: J Clin Oncol. 2006 May 10;24(14):2137-50
references: 16682732
references: Ann Oncol. 2007 Mar;18(3):581-92
references: 17287242
references: PLoS One. 2008 Jun 30;3(7):e2816
references: 18636124
references: Pharmacogenet Genomics. 2008 Nov;18(11):967-75
references: 18854778
references: Int J Cancer. 2006 Jul 15;119(2):467-71
references: 16477637
references: Clin Cancer Res. 2010 Jul 1;16(13):3473-84
references: 20570923
references: N Engl J Med. 2006 Jan 19;354(3):270-82
references: 16421368
references: J Clin Endocrinol Metab. 2007 Jun;92(6):2286-91
references: 17405848